Investor Presentaiton
RESULTS FOR 1H FY23
AUD $m
1H FY23
1H FY22
Change ($) Change (%)
Operating revenue
(1)
Operating EBITDA (2)(3)
215.1
180.5
34.6
19.2%
39.8
38.8
0.9
2.4%
Operating EBITDA margin
Operating EBITA (2)(3)
Operating NPAT (2)
Operating Diluted EPS (cps)
Free cash flow
Free cash flow conversion, after replacement capex
18.5%
21.5%
19.6
22.7
(3.1)
(13.6%)
7.8
12.3
(4.5)
(36.4%)
3.3
6.4
(3.1)
(48.0%)
38.5
24.7
13.8
56.0%
96.8%
63.6%
As at:
31 Dec 2022
31 Dec 2021
Net debt (pre-AASB 16) (4)
194.2
179.5
Net debt/pro forma EBITDA (pre-AASB 16) (4) (5)
3.1x
2.6x
Equity
370.5
267.0
103.5
38.8%
1)
2)
3)
Represents operating revenue, excluding other revenue in 1H FY23 of $0.6m (1H FY22 $1.0m).
Non-operating transactions not included in operating metrics include transaction and integration costs, share based expenses for
radiologists, amortisation of customer contracts, adjustments to non-operating provisions, and one-off system implementation costs, net of
tax of $8.3m (1H FY22: $2.5m). Refer to slide 22 for further detail.
In 1H FY23 the cost of the management LTI plan has been reallocated to operating labour costs. As such, the 1H FY22 financial information
has been restated to ensure consistency of presentation. The impact of this reallocation is a decrease of $0.2m to 1H FY23 Operating
EBITDA, Operating EBITA and Operating NPAT and a decrease of $0.6m to 1H FY22 Operating EBITDA, Operating EBITA and Operating NPAT.
4) The impact of AASB 16: Leases on 1H FY23 results was an increment to EBITDA of $8.5m, an increment to EBIT of $0.5m and a decrement to
NPAT of ($0.4m).
5)
Based on net debt at 31 December 2022 of $194.2m and LTM organic EBITDA (plus trailing acquisitions EBITDA) of $63.5m. 1H FY22 is based
on net debt at 31 December 2021 of $179.5m and LTM organic EBITDA (plus trailing EBITDA from acquisitions) of $69.7m (after LTI
reallocation refer to point 3 above).
KidxView entire presentation